As described for humans, the results obtained clearly demonstrated that serum TIM-3 levels are lower in cats with mammary carcinoma compared with healthy controls, with higher serum TIM-3 levels being associated with a better clinical outcome and higher TIM-3 expression in total and stromal TILs. Here, HAVCR2 is linked to breast carcinoma.